Lupin gets EIR from USFDA for Nagpur facility
New Delhi: Drug firm Lupin said it has received an establishment inspection report (EIR) from the US health regulator after the successful inspection of its Nagpur facility.
The plant was inspected by the United States Food and Drug Administration (USFDA) in May 2018, Lupin said in a filing to BSE.
Commenting on the development, Lupin MD Nilesh Gupta said, "The successful completion of the Nagpur facility inspection is a positive development as we continue our journey to meet and exceed international regulatory standards."
Earlier in May, in a regulatory filing, Lupin had said that the US health regulator had completed the inspection of the Nagpur facility without making any observations.
EIREstablishment Inspection ReportinspectionLupinNagpur facilityNilesh Guptano observationsUnited States Food and Drug AdministrationUSFDA
Source : PTINext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd